(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid

• ChemBase编号: 977
• 分子式: C26H29FN2O2
• 平均质量: 420.5190632
• 单一同位素质量: 420.2213064
• SMILES: Fc1ccc(C2(CCC(N3C[C@H]([C@](CC3)(c3ccccc3)C(=O)O)C)CC2)C#N)cc1
• Canonical SMILES: N#CC1(CCC(CC1)N1CC[C@]([C@@H](C1)C)(C(=O)O)c1ccccc1)c1ccc(cc1)F
• InChI: InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23?,25?,26-/m1/s1
• InChIKey: ZCGOMHNNNFPNMX-YHYDXASRSA-N

名称和登记号

名称

• IUPAC标准名: (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
• IUPAC传统名: bilina; livostin
• 商标名: Livostin
• 别名: Levocabastina [Spanish]; Levocabastin; Levocabastinum [Latin]; Levocabastine; (3S,4R)-1-(4-Cyano-4-(4-fluorophenyl)cyclohexyl)-3-Methyl-4-phenylpiperidine-4-carboxylic acid

登记号

• CAS号: 79516-68-0
• PubChem SID: 160964440; 46505909
• PubChem CID: 54385

理论计算性质

JChem

• Acid pKa: 3.7128966
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 2.4939494
• LogD (pH = 7.4): 2.499277
• Log P: 2.4994276
• 摩尔折射率: 118.4834 cm^3
• 极化性: 45.76977 Å^3
• 极化表面积: 64.33 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 4.56
• LOG S: -5.08
• 溶解度: 3.47e-03 g/l

分子性质

理化性质

• 溶解度: >0.5 mg/mL
• 疏水性(logP): 5

产品相关信息

• 纯度: 98%

详细说明

DrugBank - DB01106

• Drug Groups: approved
• Description: Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
• Indication: As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. Also used as a nasal spray for allergic rhinitis.
• Pharmacology: Levocabastine is a selective histamine H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils. Both histamine and antigens induced conjunctivitis can be inhibited by levocabastine. Levocabastine can also reduce symptoms of allergic rhinitis by preventing an increase in vascular permeability of nasal mucosa.
• Toxicity: Adverse effects include visual disturbances, dry mouth, cough, nausea, eyelid edema and lacrimation.
• Affected Organisms: Humans and other mammals
• Biotransformation: Mostly unchanged. 10 to 20% is metabolized to the acylglucuronide of levocabastine.
• Absorption: After instillation in the eye, levocabastine is systemically absorbed, albeit at low levels.
• Half Life: 36 hours (after oral administration)
• External Links: Wikipedia; RxList; Drugs.com